Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom
NCT03413579
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
37
Enrollment
INDUSTRY
Sponsor class
Conditions
Cervical Cancer
Interventions
BIOLOGICAL:
Nimotuzumab ( h-R3)
OTHER:
Placebo
Sponsor
El Kendi Pharmaceuticals Manufacturing Company